Latest Sunitinib Stories
HOUSTON, May 19 /PRNewswire/ -- Agennix announced today that talactoferrin alfa (talactoferrin) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the first-line treatment of renal cell carcinoma (RCC) in combination with sunitinib (Sutent(R) - Pfizer).
Researchers at Fox Chase Cancer Center uncovered a genetic pattern that may help predict how gastrointestinal stromal tumor (GIST) patients respond to the targeted therapy imatinib mesylate (Gleevec). Moreover, their findings point to genes that could be suppressed in order to make these tumors respond more readily to imatinib.
Sutent/Taxol Will Earn Decision Resources' Clinical Gold Standard Status for the Indication by 2012, According to a New Report from Decision Resources WALTHAM, Mass., April 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed oncologists identify a therapy's effect on overall survival as the attribute that most influences their prescribing decisions in metastatic triple-negative breast cancer.
- Afinitor more than doubled time without tumor growth and reduced the risk of disease progression or death by 67% compared with placebo - Only once-daily oral cancer treatment to directly target mTOR, a protein inside the cell that controls tumor cell division and blood vessel growth - Phase III trials underway to explore potential of Afinitor in multiple additional cancers EAST HANOVER, N.J., March 30 /PRNewswire/ -- Novartis announced today that Afinitor(R) (everolimus) tablets has been...
NCCN presented new updates to the NCCN Clinical Practice Guidelines in Oncology(TM) for Thyroid Carcinoma at the NCCN 14th Annual Conference on March 14.
Pfizer Inc. announced on Thursday that it had halted a successful trial of its cancer drug Sutent after results showed the drug slowed the progression of a rare form of pancreatic cancer.
Pfizer's Axitinib Earns Decision Resources' Gold-Standard for Renal Cell Carcinoma in 2012, According to a New Report from Decision Resources WALTHAM, Mass., Feb.
A British oncologist says he is dismayed that kidney cancer patients may be denied four new treatments due to cost. Dr.
EntreMed, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, has met the primary endpoint for the efficacy portion of the open label Phase I/II study of MKC-1 in combination with pemetrexed in non-small cell lung cancer patients.
- The act of burning, scorching, or heating to dryness; the state or being thus heated or dried.
- In medicine, cauterization.